Arthrosi Therapeutics, Inc., a late-stage biotechnology company focused on developing next-generation treatments for gout and tophaceous gout, has announced the successful closing of a $153 million Series E financing round. The investment was led by Prime Eight Capital Limited, with participation from CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech Limited, and existing shareholders.
The funding will support the completion of clinical development for Arthrosi’s lead candidate, pozdeutinurad (AR882)—a highly potent and selective URAT1 inhibitor designed to reduce serum urate (sUA) levels, prevent flares, and dissolve tophi in patients suffering from gout-related conditions.
The company plans to use the proceeds to advance two ongoing Phase 3 clinical trials, REDUCE 1 and REDUCE 2. These randomized, double-blind, placebo-controlled studies are evaluating the efficacy and safety of pozdeutinurad over a 12-month period. Primary endpoints focus on lowering sUA levels, while secondary goals include the reduction of gout flares and tophus burden. Both trials are fully enrolled, and Arthrosi expects to report pivotal data by the second quarter of 2026.
Dr. Litain Yeh, Founder and CEO of Arthrosi Therapeutics, emphasized the importance of investor confidence in the company’s mission.
“Arthrosi continues to make rapid progress on our mission to transform the treatment landscape for gout and tophaceous gout, an area with pressing unmet need,” said Yeh. “The commitment from both new and existing investors provides further validation for pozdeutinurad and the robust clinical data package we have generated to date.”
Prime Eight Capital echoed this sentiment, expressing confidence in Arthrosi’s leadership and the potential of its lead drug candidate.
“We share their vision to make pozdeutinurad accessible to patients globally and are proud to support a team with the expertise, discipline, and urgency to make that vision a reality,” the firm said in a statement.
With the Phase 3 trials now fully enrolled and financial backing secured, Arthrosi Therapeutics is positioning itself to bring a potentially best-in-class gout therapy closer to market.